WAM
AMPH icon

Wakefield Asset Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Wakefield Asset Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,128
Closed -$874K – 149
2023
Q4 		$874K Buy
+14,128
New +$742K 0.32% 96
2020
Q4 		– Sell
-27,838
Closed -$522K – 160
2020
Q3 		$522K Buy
27,838
+105
+0.4% +$2.11K 0.25% 111
2020
Q2 		$623K Buy
+27,733
New +$508K 0.3% 88

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Wakefield Asset Management's AMPH Position: Q1 2024 in Review

Wakefield Asset Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2024, closing a stake of 14,128 shares — an estimated $874K sold.

Wakefield Asset Management first reported a position in AMPH in Q2 2020 and held it in 3 quarters. The position peaked at $874K in Q4 2023. 270 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.

  • Wakefield Asset Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Wakefield Asset Management sold 14,128 Amphastar Pharmaceuticals shares in Q1 2024, an estimated $874K.
  • Wakefield Asset Management first reported a position in Amphastar Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Wakefield Asset Management's Amphastar Pharmaceuticals position peaked at $874K in Q4 2023.
  • 270 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.

Based on Wakefield Asset Management's 13F filing for Q1 2024, filed 1 May 2024.